Active Ingredients

• Sofosbuvir (400 mg): Initiating the Sofosbuvir therapy will prevent the replication of the hepatitis C virus as this is achieved by inhibiting the enzyme that is necessary for viral RNA replication. It is an energy nucleotide analog that does not allow Hepatitis C NS5B polymerase to act.
• Velpatasvir (100 mg): Velpatasvir uses non-structural protein 5A (NS5A) as the target; it serves the role of inhibiting its function, which is extremely vital for viral replication and encapsidation. It shows activity on several different hepatitis C virus genotypes and creates a barrier for virus multiplication within the body.

Manufacturer

The Velasof Tablet 400 mg + 100 mg is the product of Hetero Drugs Ltd. A reputable company that observes strict quality standards and adheres to regulatory guidelines during production. The plant has the most modern machinery that qualified workers mainly operate with the main goal of manufacturing safe and high-quality drugs.

How does this medication work?

• Absorption: 400mg Sofosbuvir and 100mg Velpatasvir (Velasof Tablet), after being ingested, are released in the intestinal tract.
• Sofosbuvir Action: Sofosbuvir, a nucleotide analog inhibitor, resembles viral RNA while in the liver and becomes active in this form. The resistive form is inserted by viral polymerase into the HCV genome failing RNA chain synthesis that is deleterious to the replication of HCV.
• RNA Chain Termination: Sofosbuvir’s active component does it by interfering with the formation of the viral RNA chain as a result of which the rate of HCV replication in the liver is lowered and the viral load is reduced.
• Velpatasvir Action: The anti-NS5A drug called velpatasvir cuts off the functions of the NS5A protein which is considered vital for both replication and assembly of viral particles.
• Inhibition of NS5A Function: Velpatasvir recomposes NS5A protein function and stymies this step of the viral replication cycle, causing a lowering of the production of infectious HCV particles and hepatic spread too.
• Synergistic Antiviral Effect: The dual mechanism action of Velasof Tablet originates from a mixture of Sofosbuvir as well as Velpatasvir, shown to be synergistic in terms of antiviral activity, resulting in RNA production as well as preventing the spread of the virus.
• Viral Clearance and Liver Recovery: If the patient is consistently treated with Velasof Tablet, the result pinpoints the disappearance of the viral causes, reduced inflammation, and regeneration of the liver. This gives rise to achieving sustained qualitative response (SVR), which means complete disappearance/aeration of the virus leading to restoration of liver health.

Velasof TabletDosage Guidelines:

Dose:

• Consume orally at once, either with or without food as a doctor may prescribe.
• Follow carefully the physician’s prescription providing the recommended therapy, as the duration and the dose should be consistent.
• The span of treatment in this regard heavily relies on genotype, prior treatment, and the condition of the liver, stretching the length of therapy from 12 weeks to 24 weeks.

Administration:

• To be taken as Velasof Tablet 400 mg and 100 mg with a full glass of water by mouth.
• Take complete the tablet by whole; do not chew, separate, or split it.
• Take Velasof Tablets with a fixed dose and at the same time daily to achieve the desired concentration of the medicine in the blood.

Special Populations:

• Elderly: Since no dose adjustment for his healthy elder population is needed, extra vigilance may be required in those with kidney or liver disease.
• Renal Impairment: No adjustment in dosage is necessary for moderate to severe renal failure. However, one should note that it can be hazardous in the situation of advanced renal insufficiency or end-stage of renal disease.
• Hepatic Impairment: When Child-Pugh A or B hepatic insufficiency is moderate to severe, no dosage adjustments are necessary, butVelasof Tablet is not suggested for use in Child-Pugh C severe hepatic impairment.
• Monitoring: Patients must be monitored regularly by checking liver function, viral load in the blood and other parameters relevant to the assessment of treatment response and the safety of the patients.

Side Effects:

• Nausea
• Headache
• Fatigue
• Insomnia
• Diarrhea
• Dizziness
• Muscle weakness
• Skin rash
• Decreased appetite
• Abdominal pain
• Liver function abnormalities
• Allergic reactions

It is crucial to recall that not all people might go through these side effects and their intensity can fluctuate. It is very important to discuss with your physician any side effects that you may encounter while taking the Velasof Tablet 400 mg + 100 mg to get the best counsel and event management options.

Interaction

Less specific data is available. To understand the interaction of the tablet in detail please contact your doctor.

Precautions to take

• Take the Velasof Tablet only under the guidance and supervision of a doctor lawfully authorized to treat HCV infection.
• Inform your doctor or healthcare provider of any known allergies you may have to the active ingredients that make up Velasof Tablet, which are Sofosbuvir and Velpatasvir.
• The tablet may not be suitable if you are pregnant, thinking of becoming pregnant, or breastfeeding. Risks or benefits should be given.
• Frequently monitor liver function, especially in people who suffer from liver disease, and diligently monitor renal function to provide dosage adjustments in case of a severe case of kidney impairment.
• Let your healthcare provider know about all medications, Vitamins and herbal products. These might interact and affect the drugs.
• You should be careful while driving or operating complex devices because you can be affected by side effects like weakness or dizziness.
• Limit alcohol consumption for it will aggravate the symptoms and influence the liver restrictions.
• The Tablet of Velasof Store should be kept at room temperature, Away from moisture and heat, And should be away from children and pets out of reach.
• Follow tightly the dosage and the treatment regimen and attend all the follow-up appointments for treatment monitoring and for dose adjustments if necessary.